Europe Cell & Gene Therapy Manufacturing Market — Growth Drivers, Restraints and Future Outlook 2032
Europe Cell & Gene Therapy Manufacturing Market valued at USD 1.8B (2023), projected USD 5.6B by 2032 at 13.5% CAGR with rising clinical trials and regulatory.
$1.8B
$5.6B
13.5%
North America
Executive Summary
The Europe Cell & Gene Therapy Manufacturing Market was valued at USD 1.8 billion in 2023 and is projected to reach USD 5.6 billion by 2032, growing at a 13.5% CAGR. Europe accounts for approximately 32% of the global cell and gene therapy manufacturing market, driven by a robust clinical pipeline, favorable regulatory pathways via the EMA, and significant investments by pharmaceutical companies in advanced manufacturing infrastructure. Germany and the United Kingdom lead regional adoption. Key players include Lonza, Oxford Biomedica, and Miltenyi Biotec. The market presents substantial investment opportunities in viral vector manufacturing, autologous cell therapy scaling, and decentralized manufacturing models, though high production costs and supply chain complexity remain notable constraints.
Key Highlights
Europe accounts for 32% of the global cell and gene therapy manufacturing market with a 13.5% CAGR through 2032.
Germany and the UK lead European adoption driven by strong pharma presence and supportive regulatory frameworks.
Contract manufacturing segment dominates at 60% market share as biotech firms outsource production to CDMOs.
Market Overview
Market Context
Europe's cell and gene therapy manufacturing sector is rapidly expanding, driven by over 200 active clinical trials, EMA regulatory support, and significant CDMO investments in advanced manufacturing platforms across the region.
Europe's cell and gene therapy manufacturing market is experiencing rapid expansion, supported by over 200 ongoing clinical trials and strong regulatory support from the EMA. The region hosts major CDMOs and biotech firms investing in next-generation manufacturing platforms. Rising approvals of CAR-T therapies and AAV-based gene therapies are key growth catalysts.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$1.8B
Forecast (2032)
$5.6B
CAGR (2024-2032)
13.5%
| Year | Market size ($ Billion) |
|---|---|
| 2023Base year | $1.80B |
| 2024 | $2.04B |
| 2025 | $2.32B |
| 2026 | $2.63B |
| 2027 | $2.99B |
| 2028 | $3.39B |
| 2029 | $3.85B |
| 2030 | $4.37B |
| 2031 | $4.96B |
| 2032 | $5.63B |
The market is projected to grow from USD 1.8 billion in 2023 to USD 5.6 billion by 2032 at a 13.5% CAGR, fueled by rising CAR-T approvals, expanding AAV gene therapy pipelines, and increasing CDMO outsourcing demand.
| Region | Market share | Growth rate | Largest market |
|---|---|---|---|
| North America | 40.0% | 12.8% | United States |
| Europe | 32.0% | 13.5% | Germany |
| Asia Pacific | 28.0% | 15.2% | China |
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Rising clinical pipeline of cell and gene therapies in Europe
- Supportive EMA regulatory frameworks and accelerated approvals
- Increased pharma investment in advanced manufacturing infrastructure
Market Segmentation
| Segment | Share |
|---|---|
| Contract ManufacturingCDMO-provided manufacturing services for pharma and biotech companies. | 60.0% |
| In-House ManufacturingPharma companies manufacturing therapies through owned facilities. | 40.0% |
| Total | 100.0% |
| Segment | Share |
|---|---|
| Cell Therapy ManufacturingIncludes autologous and allogeneic cell therapy production such as CAR-T, CAR-NK, and stem cell therapies. | 55.0% |
| Gene Therapy ManufacturingCovers viral vector-based gene therapies including AAV, lentiviral, and adenoviral vector production. | 45.0% |
| Total | 100.0% |
By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Academic and Research Institutes
- Hospitals and Clinics
Regional Analysis
North America
Lead: United StatesLargest market driven by FDA approvals, strong biotech ecosystem, and significant CDMO presence.
Europe
Lead: GermanyFast-growing market supported by EMA regulatory pathways, strong pharma presence, and rising clinical trials.
Asia Pacific
Lead: ChinaEmerging high-growth region driven by cost-effective manufacturing and increasing government investment.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| United States | 35.0% | +12.5% |
| Germany | 14.0% | +14.2% |
| China | 12.0% | +18.5% |
Competitive Landscape
Lonza
Switzerland
Global CDMO leader with major European operations, offering end-to-end cell and gene therapy manufacturing services including viral vector and CAR-T production.
Switzerland-based global CDMO leader and largest contract manufacturer of cell and gene therapies with extensive European manufacturing footprint.
Thermo Fisher Scientific
United States
Provides comprehensive gene and cell therapy manufacturing solutions through its Brammer Bio and PPD subsidiaries with expanding European footprint.
Oxford Biomedica
United Kingdom
UK-based specialist in gene and cell therapy contract development and manufacturing, with strong expertise in lentiviral and AAV vector production.
UK-based gene and cell therapy CDMO specializing in lentiviral and AAV vector manufacturing for clinical and commercial supply.
Also profiled
Miltenyi Biotec
Germany-based biotechnology company providing cell therapy manufacturing tools, reagents, and GMP-compliant processing solutions.
Recent Developments
Expanded viral vector manufacturing capacity at its Visp facility to meet growing AAV and lentiviral demand.
Signed a major gene therapy CDMO agreement with a top-10 pharma company for commercial-scale AAV production.
Regulatory Landscape
Research Methodology
Primary research
- Expert interviews with CDMO executives
- Surveys of biotech and pharma manufacturing decision-makers
Secondary research
- Industry analyst reports
- Company financial filings and press releases
Validation: Triangulation method
Strategic Takeaways
The 13.5% CAGR presents strong growth potential in viral vector and allogeneic cell therapy manufacturing segments.
Investing in single-use platforms and AI-driven bioprocess optimization will be critical for competitive differentiation.
Early partnerships with emerging biotech firms and expansion into decentralized manufacturing models offer key growth avenues.
Harmonizing cross-border GMP standards across EU member states remains essential for market efficiency.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- BiotechnologyNorth America Cell & Gene Therapy Manufacturing Market$1.2B · 16% CAGR
- BiotechnologyAsia Pacific Cell & Gene Therapy Manufacturing Market$5.7B · 16.2% CAGR
- BiotechnologyGlobal Cell & Gene Therapy Manufacturing Market$5.7B · 12.2% CAGR
- BiotechnologyUnited States Cell & Gene Therapy Manufacturing Market$11.4B · 34.1% CAGR
- BiotechnologyGlobal Europe Gene Therapy Market$1.4B · 20% CAGR
- BiotechnologyGlobal Asia Pacific Gene Therapy Market$1.4B · 21% CAGR